While active acquisition is perhaps the most common methodology of gaining wealth, it's not always the most efficient. For example, even if you trade your hours for a generous paycheck, there are only so many hours available: in a day, in a week, in a month, you get the idea.
Drugmaker AbbVie has been investing in its growth, and that strategy looks to be paying off. Verizon's stable business and low valuation make it practically a no-brainer buy for dividend investors.
At this writing, current inflation rate is 3% over the past 12 months. That's the reading as of the end of June.
U.S. News & World Report recently said the New York Fed's Recession Probability model hints that within the next 12 months, we stand a 55.8% chance of a recession. One can never be too safe though.
AbbVie (ABBV) files regulatory applications to the FDA and the EMA, seeking approval for a new indication of Rinvoq, giant cell arteritis.
Trump confirms he is "fine" after assassination attempt during rally in Pennsylvania, suspect dead. Global leaders condemn violence, wish Trump speedy recovery.
AbbVie is poised to keep a 52-year streak of dividend hikes going. Amgen offers more than a dividend with its promising pipeline.
Johnson & Johnson and AbbVie produce reliable earnings driven by sales of patent-protected drugs. Real estate investment trust Agree Realty makes monthly dividend payments.
Investors who own AbbVie's (ABBV) stock may stay invested as the company has faced its biggest challenge, Humira's patent cliff- quite well and looks set to return to robust growth next year.
Dividend stocks are a favorite among investors for good reasons.
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
One of these stocks is a Dividend King poised to deliver solid growth for years to come. Another offers an ultra-high dividend yield of 9.2% and has a big growth opportunity.